AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01245673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlamid® (Lenalidomide)
Description: At about day 100 post-transplant, after completion of post-transplant immunological assessments and myeloma restaging studies, patients will be eligible to receive low-dose Revlamid® (Lenalidomide) 10 mg/day for maintenance therapy (10 mg/day) until progression of myeloma or development of intolerance.
Study NCT03726450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andrositol Plus
Description: Folic Acid
Study NCT03726450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andrositol Plus
Description: Selenium
Study NCT03726450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andrositol Plus
Description: L-arginine
Study NCT03726450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andrositol Plus
Description: L-carnitine
Study NCT03726450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andrositol Plus
Description: Vitamin E
Study NCT02980952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat overfeeding
Study NCT02980952 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Forearm immobilization
Study NCT02980952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forearm immobilization
Study NCT03995251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Supplementation
Description: Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
Study NCT03995251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study NCT03995251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study NCT03995251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise
Study NCT03995251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise
Study NCT02516540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured exercise training plus mediterranean diet
Description: Structured exercise training plus mediterranean diet
Study NCT02108340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave radiometry
Description: Microwave radiometry of the right lower quadrant in a room temperature of 20-24 degrees celsius, in order to record changes in the temperature of the inflamed appendix.
Study NCT00660881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only PBS as a vehicle/buffer for the infusion procedure.
Study NCT00955305 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV
Study NCT00955305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00955305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT00955305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00955305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV
Study NCT00955305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT00955305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT05949034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUUL E-Cigarette Device
Description: We will use the commercially available and popular JUUL e-cigarette device and e-cigarette solutions.
Study NCT02624947 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSV F vaccine with adjuvant
Study NCT02624947 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Formulation buffer
Study NCT00956098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oltipraz
Description: 60mg bid 90mg qd
Study NCT00956098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00588159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: gabapentin 600 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
Study NCT00588159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine 12.5 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
Study NCT01245673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)
Description: After study enrollment, patients will receive both MAGE-A3/GM-CSF \[+ coinjection of 2mg of Hiltonol®(Poly-ICLC)\]. At Day #14, Day #42, Day #90, Day #120 and Day #150 patients will receive an additional immunization with MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC).
Study NCT00355121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL IM of each vaccine. (DAPTACEL® + IPOL on Day 0 and Menactra on Day 30)
Study NCT00355121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, IM of each vaccine. (DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30)
Study NCT00355121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, IM of each vaccine (Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30)
Study NCT04531384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robot-assisted rehabilitation intelligent treatment
Description: robot-assisted rehabilitation psychotherapy
Study NCT04531384 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard psychotherapy treatment
Description: standard treatment at the compulsory isolated detoxification centers and non-compulsory isolated detoxification institutions
Study NCT01796002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin + CHOP
Description: Ro-CHOP administered in 3 week cycles for 6 cycles or until progression Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks.
Study NCT01796002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Description: CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 6 cycles.
Study NCT03541473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Peptamen® 1.5 Vanilla
Description: Nutritionally complete formula with 10g MCT in 250 mL, commercially available
Study NCT03541473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Boost Plus® Vanilla
Description: Product of same nutritional composition but without MCT
Study NCT03114449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Auricular acupuncture with indwelling fixed needles at specific AA points
Study NCT03114449 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham auricular acupuncture
Description: Sham auricular acupuncture (AA) with indwelling fixed needles applied at non-AA points
Study NCT04011202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality gaming program (VR-gaming program)
Description: Participants in the VR-gaming program will receive three 20-30 minutes sessions of VR-gaming per week for the duration of their inpatient stay. Participants will select VR games/program in categories of: Relaxation; Leisure sport and activities; or Action/adventure. The VR-gaming program will be implemented one-on-one, face-to-face by a clinician using the commercially-available Oculus Go system.
Study NCT02617355 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prototype surgical magnetic drape
Description: New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax
Study NCT02617355 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Green Covidien Magnetic Drape
Description: Green Covidien Magnetic Drape applied to the patient's thorax
Study NCT02617355 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Jac-Cell Medic Reusable Magnetic Pad
Description: Jaa-Cell Medic Reusable Magnetic Pad applied to the patient's thorax
Study NCT01221922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RevLite Q-Switched Nd:YAG Laser
Description: Laser treatment once every 2 weeks for a total of 10 treatments.
Study NCT01316549 — intervention group
Intervention type: DRUG
Intervention: Fludarabine
Description: Given as injection
Study NCT05345236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal (IVT) injection
Study NCT05345236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intravitreal (IVT) injection
Study NCT01530620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propiverine hydrochloride ER (extended release)
Description: 45 mg capsule (1x1/d)
Study NCT01530620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propiverine hydrochloride IR (immediate release)
Description: 15 mg tablet (3x1/d)
Study NCT04577846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin 500 MG
Description: Cefalexin 500 mg PO q8 hours will be continued for the duration of the indwelling drains which usually is about 14 days.
Study NCT04577846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo capsule filled with inert material for the duration of the drains which usually is about 14 days.
Study NCT01313273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide, non steroidal anti androgens and LHRH-a
Description: Lanreotide 120 mg. Injection every 28 days, to be administered till progression or for a maximum of 24 months.~Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression.
Study NCT01313273 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Non steroidal anti androgens and LHRH-a
Description: Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression
Study NCT03879915 — intervention group
Intervention type: PROCEDURE
Intervention: Dental Implant placement
Description: Surgical placement of dental implant not associated with prior or concurrent bone augmentation
Study NCT03957239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranberry Beverage
Description: The cranberry beverage will provide 50 kcals and 4.0 grams of fiber per day from whole milled cranberries, water, cranberry natural flavor and sucralose.
Study NCT03957239 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Beverage
Description: The control beverage will provide 50 kcals per day and is a color, taste matched sugar sweetened beverage formulated with water, sucrose, citric acid, cranberry natural flavor, malic acid, xanthum gum, sucralose and artificial color (red 40, blue 1).
Study NCT03269409 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lactated Ringers
Description: Approximately 5 mls of lactated ringers will be injected after decompression into the hip that does not receive adipose derived regenerative cells.
Study NCT03269409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Celution 800/GP System (Cytori Therapeutics)
Description: The Celution 800/GP System will be used for the preparation of adipose derived regenerative cells from lipoaspirate. The adipose derived regenerative cells will then be transplanted into the hip, post decompression.
Study NCT03269409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose Derived Regenerative Cells (ADRC)
Description: Subjects in this arm will have Adipose Derived Regenerative Cells (ADRC)harvested through autologous liposuction and processed outside the body using The Celution 800/GP System (Cytori Therapeutics) before having approximately 5 mls. of ADRCs transplanted into the femoral head after standard of care hip decompression.
Study NCT02613260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIT Outreach
Description: This arm will consist of priming patients with a postcard and a possibly a phone call two weeks prior to them being mailed a FIT kit. The FIT kits will be mailed to the patients with a letter from their clinic's care team informing them why they should complete the FIT and wordless instructions to help them complete the FIT. Two weeks after the FIT kit is mailed the patients that have not returned the kit will receive up to two reminder calls. During the phone calls the outreach workers will use health coaching techniques to encourage patients to complete the FIT. All written materials have been translated into English and Chinese and during phone calls patients will be spoken to in the language that they are most comfortable using.
Study NCT04615793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILATES EXERCISES
Description: The experimental group will receive Pilates exercises focusing on lower limb strength, flexibility and coordination in addition to exercises given to control group. Exercises or movements were done on a mat, on an exercise ball or in standing position while emphasizing on spinal and pelvic alignment, maintaining core contraction and the rhythm of respiration. All exercises were done for 10 repetitions with a rest period of two minutes before commencing the next exercise, and lasted for about 45 minutes. All the groups will receive the above mentioned interventions thrice in a week for a period of 10 week
Study NCT00614471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: 0.5mg po daily for 24 weeks
Study NCT00614471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: 0.5mg po daily from week 13 to week 36
Study NCT00614471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc/week for 48 weeks
Study NCT00614471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc/week for 48 weeks
Study NCT00614471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc/week from week 21 to week 68
Study NCT03352271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized Incremental hemodialysis
Description: Individualized Incremental hemodialysis program (twice/week, once/week, once/10days or less frequent) will be provided to incident ESRD patients according to their symptom presentation, clinical examination, investigations and daily urine volume measurement.
Study NCT03352271 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional thrice weekly hemodialysis
Description: Thrice weekly hemodialysis program, the current standard of care for all patients, as a control
Study NCT03589170 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Opportunistic atrial fibrillation screening
Description: Opportunistic pulse palpation and/or ECG at least once a year when they visit doctors or nurse for other reasons.
Study NCT04256122 — intervention group
Intervention type: OTHER
Intervention: No intervantion on patients. retrospective study is performed on paraffin embedded tumor tissue specimens routinely collected during TURBT.
Description: evaluate an immunophenotypical profile related to mitochondrial functions in tumors responders vs non-responder to intravescical chemotherapy or immunotherapy. Verify the possible prognostic differences in clinical behavior between the two populations.
Study NCT02617355 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DeRoyal Magnetic Pad size 20 x 16
Description: Magnetic Instrument Pad #25-002, size 20 x 16, DeRoyal Industries Inc applied to the patient's thorax
Study NCT02617355 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DeRoyal Magnetic Pad size 10 x 16
Description: Magnetic Instrument Pad #25-001, size 10 x 16, DeRoyal Industries Inc applied to the patient's thorax
Study NCT02598882 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: videogame
Description: Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute guided activity through an active video game
Study NCT02598882 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treadmill
Description: Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute activity in treadmill.
Study NCT01249222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plasmapheresis
Description: Plasmapheresis was done every 24-48 hours and continues up to five times. Blood samples were collected 30 minutes before and after each session of plasmapheresis to determine sequential changes in plasma levels of IL-1β, IL-6 and TNF-α. During each exchange session a volume of 25-30 ml/kg bodyweight of patient's plasma was exchanged with equal volume of 20% human albumin diluted with normal saline solution. Before and after plasmapheresis, prothrombin time, activated partial thromboplastin time (aPTT), platelet count and serum calcium level were checked. calcium gluconate 10% (10 ml) was administered even if patient had normal serum calcium in order to prevent hypocalcaemia due to administration of citrate. All drugs except for vasopressors were stopped during procedure.
Study NCT01249222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plasmapheresis
Description: plasmapheresis 5 times every 24-48 hours. the apheresis volume will be 30 ml/kg.
Study NCT01249222 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: plasmapheresis
Description: plasmapheresis 5 times every 24-48 hours. the apheresis volume will be 30 ml/kg.
Study NCT01330186 — intervention group
Intervention type: OTHER
Intervention: FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI)
Description: This study involves 6 imaging sessions. One FMISO-PET before radiation therapy, one FDG-PET-CT before radiation therapy and one FDG-PET-CT during radiation therapy and tree Magnetic Resonance imaging (MRI) sessions with one session before radiation therapy, one session during radiation therapy and one sessions post radiation.
Study NCT02150694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm venous occlusion plethysmography
Description: Forearm venous occlusion plethysmography to study to measure forearm blood flow during intra-arterial infusion of the apelin peptides.
Study NCT01667263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Study NCT02150694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aellig hand vein technique
Description: Hand vein measurements will be used to assess the response to apelin peptides and apelin receptor blocker in the human hand vein vascular bed.
Study NCT02150694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apelin agonist infusion
Description: Escalating doses of apelin (1/10/100nmol/min) will be administered.
Study NCT02150694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apelin receptor antagonist infusion
Description: Dose finding study (range 1-300nmol/min) and co-infusion study with apelin peptides
Study NCT00523263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: heparin-bonded and collagen coated polyster
Description: femoro-popliteal bypass
Study NCT03518905 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation is performed using the Barrx Channel endoscopic catheter (Medtronic, Dublin, Republic of Ireland) generating an energy density level of 12 Joule/cm2. The energy is applied using a simplified protocol of three ablations without removal of coagulated tissue. The device is used on a routinely basis all around the world and already approved. The ablation catheter is applied through the working channel of the endoscope.
Study NCT03518905 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: esophagoscopy
Description: Patients receive an esophagoscopy without radiofrequency ablation under sedation
Study NCT03726866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1
Description: D326, D337 or CKD-828 for 9 days
Study NCT03726866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2
Description: D326, D337 or CKD-828 for 9 days
Study NCT03726866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3
Description: D326, D337 or CKD-828 for 9 days
Study NCT03726866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4
Description: D326, D337 or CKD-828 for 9 days